Causal inference and explainable machine learning for analyzing treatment side effect in metastatic castration-resistant prostate cancer patients
Egyptian Informatics Journal · 2026-03 · 33 · 100895
DOI: 10.1016/j.eij.2026.100895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Egyptian Informatics Journal, 2026-03. Verfasst von Olutomilayo Olayemi Petinrin und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: City University of Hong Kong, Birmingham City University, Shenzhen Research Institute of Big Data.
Themen: Künstliche Intelligenz in der Pflege, Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- City University of Hong Kong
- Birmingham City University
- Shenzhen Research Institute of Big Data
- National Natural Science Foundation of China
Zitieren
APA
Petinrin, O. O., Saeed, F., Xue, H., Basu, S., Basurra, S., Liu, Z., Toseef, M., Muyide, I. O., & Wong, K. (2026). Causal inference and explainable machine learning for analyzing treatment side effect in metastatic castration-resistant prostate cancer patients. Egyptian Informatics Journal, 33, 100895. https://doi.org/10.1016/j.eij.2026.100895
Vancouver
Petinrin OO, Saeed F, Xue H, Basu S, Basurra S, Liu Z, et al. Causal inference and explainable machine learning for analyzing treatment side effect in metastatic castration-resistant prostate cancer patients. Egyptian Informatics Journal. 2026;33:100895. doi:10.1016/j.eij.2026.100895
BibTeX
@article{Petinrin2026,
author = {Petinrin, Olutomilayo Olayemi and Saeed, Faisal and Xue, Hao and Basu, Sumanta and Basurra, Shadi and Liu, Zhe and Toseef, Muhammad and Muyide, Ibukun Omotayo and Wong, Ka-Chun},
title = {Causal inference and explainable machine learning for analyzing treatment side effect in metastatic castration-resistant prostate cancer patients},
journal = {Egyptian Informatics Journal},
year = {2026},
volume = {33},
pages = {100895},
doi = {10.1016/j.eij.2026.100895}
}
EUVIMED